Skip to main content

Advertisement

Table 5 Sensitivity analyses

From: Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

   Univariate odds ratio (95% CI) Predictive accuracy (AUC)
Definition of advanced cancer Number of cases/controls Total PSA (ng/ml) Free to total PSA (%) Total PSA (ng/ml) Free to total PSA (%) Multivariable model
Metastases or ≥ T3 161/436 4.29 (2.98, 6.18) 0.92 (0.89, 0.95) 0.791 0.641 0.785
Less inclusive* 62/163 3.02 (1.87, 4.90) 0.90 (0.84, 0.95) 0.762 0.674 0.751
More inclusive† 190/512 4.05 (2.89, 5.67) 0.92 (0.89, 0.95) 0.782 0.645 0.780
  1. * Presence of skeletal metastases at time of diagnosis.
  2. † Presence of any of the following criteria at time of diagnosis: skeletal metastasis, clinical stage at least T3, positive lymph node, WHO grade III.